Maintenance therapy for AML after allogeneic HCT

被引：6

作者：

Nayak, Rahul K. K. ^{[1
]}

Chen, Yi-Bin ^{[2
]}

机构：

[1] Massachusetts Gen Hosp, Dept Med, Boston, MA USA

[2] Massachusetts Gen Hosp, Hematopoiet Cell Transplant & Cell Therapy Program, Boston, MA 02114 USA

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

AML; acute myeloid leukaemia; maintenance; relapse; transplant; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELL TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGENS; INTERNAL TANDEM DUPLICATION; LENALIDOMIDE MAINTENANCE; RELAPSE; SORAFENIB; DISEASE; IMPACT; ALLOREACTIVITY;

D O I：

10.3389/fonc.2022.895771

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid leukemia (AML) in first complete remission is a central treatment paradigm to achieve durable remission. However, disease relapse after allo-HCT remains a significant concern and generally portends a poor prognosis. There is significant interest regarding the role for maintenance therapy after allo-HCT for patients with high risk of relapse, regardless of the presence of measurable residual disease. While there are currently no therapies approved for maintenance therapy for AML after allo-HCT, there are a number of ongoing investigations examining the role of maintenance therapies that include targeted agents against FLT3-ITD or IDH mutations, hypomethylating agents, immunomodulatory therapies and cellular therapies. In this review, we examine the current landscape and future strategies for maintenance therapy for AML after allo-HCT.

引用

页数：11

共 57 条

[1] Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation
Alsina, Melissa
Becker, Pamela S.
Zhong, Xiaobo
Adams, Alexia
Hari, Parameswaran
Rowley, Scott
Stadtmauer, Edward A.
Vesole, David H.
Logan, Brent
Weisdorf, Daniel
Qazilbash, Muzaffar
Popplewell, Leslie L.
McClune, Brian
Bensinger, William
Riches, Marcie
Giralt, Sergio A.
Pasquini, Marcelo C.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (08) : 1183 - 1189
[2] Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience
Ambinder, Alexander
Smith, Matthew
Tsai, Hua-Ling
Varadhan, Ravi
DeZern, Amy
Dalton, William
Gocke, Christian
Webster, Jonathan
Gondek, Lukasz
Gojo, Ivana
Ali, Syed Abbas
Huff, Carol Ann
Swinnen, Lode
Wagner-Johnston, Nina
Showel, Margaret
Prince, Gabrielle
Borrello, Ivan
Bolanos-Meade, Javier
Luznik, Leo
Jain, Tania
Imus, Philip
Fuchs, Ephraim
Ambinder, Richard
Gladstone, Douglas E.
Levis, Mark
Jones, Richard
Ghiaur, Gabriel
Smith, B. Douglas
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (04) : 260 - 269
[3] Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Araki, Daisuke
Wood, Brent L.
Othus, Megan
Radich, Jerald P.
Halpern, Anna B.
Zhou, Yi
Mielcarek, Marco
Estey, Elihu H.
Appelbaum, Frederick R.
Walter, Roland B.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04) : 329 - +
[4] Vaccine therapy in hematologic malignancies
Avigan, David
Rosenblatt, Jacalyn
[J]. BLOOD, 2018, 131 (24) : 2640 - 2650
[5] Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Bazarbachi, Ali
Bug, Gesine
Baron, Frederic
Brissot, Eolia
Ciceri, Fabio
Abou Dalle, Iman
Dohner, Hartmut
Esteve, Jordi
Floisand, Yngvar
Giebel, Sebastian
Gilleece, Maria
Gorin, Norbert-Claude
Jabbour, Elias
Aljurf, Mahmoud
Kantarjian, Hagop
Kharfan-Dabaja, Mohamed
Labopin, Myriam
Lanza, Francesco
Malard, Florent
Peric, Zinaida
Prebet, Thomas
Ravandi, Farhad
Ruggeri, Annalisa
Sanz, Jaime
Schmid, Christoph
Shouval, Roni
Spyridonidis, Alexandros
Versluis, Jurjen
Vey, Norbert
Savani, Bipin N.
Nagler, Arnon
Mohty, Mohamad
[J]. HAEMATOLOGICA, 2020, 105 (06) : 1507 - 1516
[6] Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis
Bewersdorf, Jan Philipp
Allen, Cecily
Mirza, Abu-Sayeef
Grimshaw, Alyssa A.
Giri, Smith
Podoltsev, Nikolai A.
Gowda, Lohith
Cho, Christina
Tallman, Martin S.
Zeidan, Amer M.
Stahl, Maximilian
[J]. TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (12): : 997.e1 - 997.e11
[7] Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
Brunet, Salut
Labopin, Myriam
Esteve, Jordi
Cornelissen, Jan
Socie, Gerard
Iori, Anna P.
Verdonck, Leo F.
Volin, Liisa
Gratwohl, Alois
Sierra, Jorge
Mohty, Mohamad
Rocha, Vanderson
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (07) : 735 - 741
[8] Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
Brunner, Andrew M.
Li, Shuli
Fathi, Amir T.
Wadleigh, Martha
Ho, Vincent T.
Collier, Kerry
Connolly, Christine
Ballen, Karen K.
Cutler, Corey S.
Dey, Bimalangshu R.
El-Jawahri, Areej
Nikiforow, Sarah
McAfee, Steven L.
Koreth, John
Deangelo, Daniel J.
Alyea, Edwin P.
Antin, Joseph H.
Spitzer, Thomas R.
Stone, Richard M.
Soiffer, Robert J.
Chen, Yi-Bin
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) : 496 - 504
[9] Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Buckley, Sarah A.
Wood, Brent L.
Othus, Megan
Hourigan, Christopher S.
Ustun, Celalettin
Linden, Michael A.
DeFor, Todd E.
Malagola, Michele
Anthias, Chloe
Valkova, Veronika
Kanakry, Christopher G.
Gruhn, Bernd
Buccisano, Francesco
Devine, Beth
Walter, Roland B.
[J]. HAEMATOLOGICA, 2017, 102 (05) : 865 - 873
[10] Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
Bug, G.
Burchert, A.
Wagner, E-M
Kroeger, N.
Berg, T.
Gueller, S.
Metzelder, S. K.
Wolf, A.
Huenecke, S.
Bader, P.
Schetelig, J.
Serve, H.
Ottmann, O. G.
[J]. LEUKEMIA, 2017, 31 (11) : 2523 - 2525

← 1 2 3 4 5 6 →